NRX Pharmaceuticals
NRXP
18 hedge funds and large institutions have $1.21M invested in NRX Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 4 closing their positions.
38% more call options, than puts
Call options by funds: $181K | Put options by funds: $131K
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
1.78% more ownership
Funds ownership: 4.86% → 6.64% (+1.8%)
5% less funds holding
Funds holding: 19 → 18 (-1)
6% less capital invested
Capital invested by funds: $1.29M → $1.21M (-$78.4K)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$287K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$70.6K |
| 3 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$44.3K |
| 4 |
TC
TownSquare Capital
Provo,
Utah
|
+$30.3K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$23.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$42K |
| 2 |
NPT
National Philanthropic Trust
Jenkintown,
Pennsylvania
|
-$24.5K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$10K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.11K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.58K |
NRXP Hedge Fund Activity: Q3 2024 in Review
18 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q3 2024, worth a combined $1.21M — down 6.1% from $1.29M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of NRXP and 3 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 4 added.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $287K. The largest seller was Virtu Financial, exiting entirely with an estimated $42K sold.
- 18 institutional investors held NRX Pharmaceuticals (NRXP) as of Q3 2024, down from 19 in Q2 2024.
- Funds reported $1.21M of NRX Pharmaceuticals stock for Q3 2024, down 6.1% quarter-over-quarter.
- 3 funds opened new NRX Pharmaceuticals positions in Q3 2024 and 4 closed out, a net change of -1 holder.
- The largest NRX Pharmaceuticals buyer in Q3 2024 was Anson Funds Management, an estimated $287K added.
- The largest NRX Pharmaceuticals seller in Q3 2024 was Virtu Financial, an estimated $42K sold.
Based on aggregated 13F filings for Q3 2024.